Silence is the only listed RNAi player in Europe and a pioneer in this technology. Through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger RNAi in specific cell types. Our inventions are protected by a broad intellectual property estate, which is a fundamental asset. Together with our progress, the fact that the field is generally maturing means that RNAi drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients.
Annual Report 2018Download
Half Year Results 2019345KB Download
Full Year Results 2018371KB Download
Half Year Results 2018367KB Download
Full Year Results 2017298KB Download
Half Year Results 2017154KB Download
Annual Report 20183MB Download
Annual Report 20172MB Download
Annual Report 20161MB Download
Annual Report 2015978KB Download
Annual Report 20149MB Download
Corporate Presentation - November 20191MB Download
Scientific Sessions 2019 - A Novel Short Interfering Ribonucleic Acid Shows Potent And Sustained Reduction Of Serum Lipoprotein(a) In Cynomolgus Monkeys746KB Download
Collaboration with Mallinckrodt Pharmaceuticals in Complement-mediated Diseases834KB Download
Silence - 2019 Keystone Symposium on Small Regulatory RNAs496KB Download
Our Corporate Governance framework is based on using the leadership provided by our Board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed.
We have three Board Committees (Remuneration, Audit and Risk, and Nominations), focused on providing the required oversight to maintaining the highest Corporate Governance standards. Through these committees and regular interactions with the executive team, our Board applies internal financial controls and approves the Company’s policy and strategy.